Rheumatoid Arthritis References

Last updated: 10 June 2024
  1. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep;69(9):1580-1588. doi: 10.1136/ard.2010.138461. PMID: 20699241
  2. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007 Nov;66(Suppl 3):iii2-22. http://www.ncbi.nlm.nih.gov. PMID: 17934088
  3. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med. 2007 Nov;120(11):936-939. http://www.ncbi.nlm.nih.gov/pubmed/17976416. PMID: 17976416
  4. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar;63(3):573-586. doi: 10.1002/art.30129. PMID: 21294106
  5. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008 Jun;59(6):762-784. doi: 10.1002/art.23721. PMID: 18512708
  6. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. May 05, 2010. Ann Rheum Dis. 2010 Jun;69(6):964-975. http://www.ncbi.nlm.nih.gov/pubmed/20444750. PMID: 20444750
  7. Singh JA, Furst DE, Bharat A, et al. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May;64(5):625-639. http://www.ncbi.nlm.nih.gov/pubmed/?term=22473917. PMID: 22473917
  8. National Institute for Health and Clinical Excellence (NICE). Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a TNF inhibitor. NICE. http://www.nice.org.uk/guidance/ta195/resources/guidance-adalimumab-etanercept-infliximab-rituximab-and-abatacept-for-the-treatment-of-rheumatoid-arthritis-after-the-failure-of-a-tnf-inhibitor-pdf. Aug 2010.
  9. National Institute for Health and Clinical Excellence (NICE). Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. NICE. http://www.nice.org.uk/guidance/ta130/resources/guidance-adalimumab-etanercept-and-infliximab-for-the-treatment-of-rheumatoid-arthritis-pdf. Sep 2010.
  10. National Institute for Health and Care Excellence (NICE). Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234). NICE. http://www.nice.org.uk/nicemedia/live/14155/63676/63676.pdf. Apr 2013. Accessed 04 Jul 2013.
  11. Venables PJW, Maini RN. Clinical features of rheumatoid arthritis. UpToDate. http://www.uptodate.com/index. 16 Feb 2011. Accessed 15 Apr 2011.
  12. National Institute for Health and Clinical Excellence (NICE). Certolizumab pegol for the treatment of rheumatoid arthritis. NICE. http://www.nice.org.uk/guidance/ta186/resources/guidance-certolizumab-pegol-for-the-treatment-of-rheumatoid-arthritis-pdf. Feb 2010.
  13. UCB Pharma Inc. Certolizumab pegol: highlights of prescribing information. US FDA. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125160s0142lbl.pdf. 2008. Accessed 05 Jul 2013.
  14. Schur PH, Maini RN, Moreland LW. General principles of management of rheumatoid arthritis. UpToDate. http://www.uptodate.com/index. Feb 2011. Accessed 16 Apr 2011.
  15. Scottish Intercollegiate Guidelines Network (SIGN). Management of early rheumatoid arthritis. SIGN. http://www.sign.ac.uk. Feb 2011. Accessed 15 Apr 2011.
  16. Venables PJW, Maini RN. Diagnosis and differential diagnosis of rheumatoid arthritis. UpToDate. http://www.uptodate.com/. 23 Nov 2010. Accessed 15 Apr 2011.
  17. Schur PH, Maini RN, Gibofsky A. Nonpharmacologic and preventive therapies of rheumatoid arthritis. UpToDate. http://www.uptodate.com/index. Dec 2010. Accessed 15 Apr 2011.
  18. National Institute for Health and Clinical Excellence (NICE). Tocilizumab for the treatment of rheumatoid arthritis. NICE. http://www.nice.org.uk/guidance/ta198/resources/guidance-tocilizumab-for-the-treatment-of-rheumatoid-arthritis-pdf. Aug 2010.
  19. Smolen JS, Landewé R, Breedveld FC, Buch M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. PMID: 24161836
  20. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2016 Jan;75(1):3-15. http://ard.bmj.com/content/early/2015/05/12/annrheumdis-2015-207524.full.pdf. Accessed 04 Sep 2015. PMID: 25969430
  21. Ritter J, Lewis L, Timothy M, et al. Anti-inflammatory drugs and the treatment of arthritis. In: Hodder A. A Textbook in Clinical Pharmacology and Therapeutics. 5th ed. London, UK: Hodder Education; 2008:170.
  22. Singh JA, Saag KG, Bridges SL Jr, et al; American College of Rheumatology. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. doi: 10.1002/acr.22783. Accessed 06 Jun 2016. PMID: 26545825
  23. McInnes IB. Cytokine networks in rheumatic diseases: implications for therapy. UpToDate. http://www.uptodate.com. Aug 2018. Accessed 28 Sep 2018.
  24. Moreland LW, Cannella A. General principles of management of rheumatoid arthritis in adults. UpToDate. https://www.uptodate.com. May 2018. Accessed 28 Sep 2018.
  25. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct;388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. Accessed 28 Sep 2018. PMID: 27156434
  26. England BR, Tiong BK, Bergman MJ, et al. 2019 Update of the American College of Rheumatology recommended rheumatoid arthritis disease activity measures. Arthritis Care Res (Hoboken). 2019 Dec;71(12):1540-1555. doi: 10.1002/acr.24042. PMID: 31709779
  27. Ministry of Health Malaysia, Malaysian Society of Rheumatology, Academy of Medicine Malaysia. Clinical practice guidelines. Management of rheumatoid arthritis. Academy of Medicine of Malaysia. http://www.acadmed.org.my. 2019. Accessed 04 Feb 2020.
  28. Smolen JS, Landewé RBM, Bijlsma JWJ, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):685-699. doi: 10.1136/annrheumdis-2019-216655. Accessed 04 Feb 2020. PMID: 31969328
  29. U.S. Food & Drug Administration. Biosimilar product information. US FDA. https://www.fda.gov/. 24 Feb 2020. Accessed 28 Feb 2020.
  30. New long-term data from Rinvoq (Upadacitinib, 15 mg) phase 3 studies in rheumatoid arthritis presented at 2020 Annual European E-Congress of Rheumatology (EULAR). Abbvie News Center. https://news.abbvie.com/. 04 Jun 2020.
  31. Taylor PC, Keystone EC, van der Heijde D, et al. Baricitinib versus placebo or Adalimumab in rheumatoid arthritis. N Engl J Med. 2017 Feb 16;376(7):652-662. doi: 10.1056/NEJMoa1608345. PMID: 28199814
  32. Furer V, Rondaan C, Heijstek MW, et al. 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases. Ann Rheum Dis. 2020 Jan;79(1):39-52. doi: 10.1136/annrheumdis-2019-215882. Accessed 6 Jul 2020. PMID: 31413005
  33. Cheung TT, McInnes IB. Future therapeutic targets in rheumatoid arthritis?. Semin Immunopathol. 2017 Jun;39(4):487-500. doi: 10.1007/s00281-017-0623-3. Accessed 9 Jul 2020. PMID: 28451787
  34. Fleischmann R, Mysler E, Hall S, et al. Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trial. Lancet. 2017 Jul;390(10093):457-468. doi: 10.1016/S0140-6736(17)31618-5. Accessed 9 Jul 2020. PMID: 28629665
  35. Fleischmann R, Pangan AL, Song IH, et al. Upadacitinib versus placebo or adalimumab in patients with rheumatoid arthritis and an inadequate response to methotrexate: results of a phase III, double-blind, randomized controlled trial. Arthritis Rheumatol. 2019 Nov;71(11):1788-1800. doi: 10.1002/art.41032. Accessed 09 Jul 2020. PMID: 31287230
  36. Strand V, Lee EB, Fleischmann R, et al. Tofacitinib versus methotrexate in rheumatoid arthritis: patient-reported outcomes from the randomised phase III ORAL Start trial. RMD Open. 2016 Sep;2(2):e000308. doi: 10.1136/rmdopen-2016-000308. Accessed 9 Jul 2020. PMID: 27752357
  37. Fraenkel L, Bathon JM, England BR, et al. 2021 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2021 Jul;73(7):924-939. doi: 10.1002/acr.24596. PMID: 34101387
  38. Rubbert-Roth A, Enejosa J, Pangan AL, et al. Trial of upadacitinib or abatacept in rheumatoid arthritis. N Engl J Med. 2020 Oct;383(16):1511-1521. doi: 10.1056/nejmoa2008250. PMID: 33053283
  39. Adam Rindfleisch J, Muller D. Diagnosis and management of rheumatoid arthritis. Am Fam Physician. 2005 Sep 15;72(6):1037-1047. https://www.aafp.org.
  40. American College of Rheumatology (ACR). 2022 American College of Rheumatology (ACR) guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis guideline summary. ACR. https://www.rheumatology.org. 31 Oct 2022.
  41. Chauhan K, Jandu JS, Goyal A, et al. Rheumatoid arthritis. StatPearls. https://www.ncbi.nlm.nih.gov. 04 Jun 2022.
  42. England BR, Mikuls TR. Epidemiology of, risk factors for, and possible causes of rheumatoid arthritis. UpToDate. https://www.uptodate.com. 08 Aug 2022. Accessed 05 Dec 2022.
  43. Hidayat R, Suryana BPP, Wijaya LK, et al. Indonesian Rheumatology Association (IRA) recommendations for diagnosis and management of rheumatoid arthritis. Ina J Rheum. 2021;13(1):322-443. https://journalrheumatology.or.id/.
  44. Ho CTK, Mok CC, Cheung TT, et al. Management of rheumatoid arthritis: 2019 updated consensus recommendations from the Hong Kong Society of Rheumatology. Clin Rheumatol. 2019 Dec;38(12):3331-3350. doi: 10.1007/s10067-019-04761-5. PMID: 31485846
  45. Smolen JS, Landewe RBM, Bergstra SA, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update. Ann Rheum Dis. 2023 Jan;82(1):3-18. doi: 10.1136/ard-2022-223356. PMID: 36357155
  46. Aletaha D, Smolen JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA. 2018 Oct;320(13):1360-1372. doi: 10.1001/jama.2018.13103. Accessed 16 Aug 2023. PMID: 30285183
  47. Caporali R, Aletaha D, Sanmarti R, et al. Long-term efficacy of Baricitinib in patients with rheumatoid arthritis who have had inadequate response to csDMARDs: results from RA-BEYOND up to 7 years of treatment. Ann of Rheum Dis. 2022;81(Suppl 1):630-631. doi: 10.1136/annrheumdis-2022-eular.4546.
  48. Currier BL, Coblyn J. Cervical subluxation in rheumatoid arthritis. UpToDate. https://www.uptodate.com. 08 Dec 2021.
  49. Dougados M, van der Heijde D, Chen YC, et al. Baricitinib in patients with inadequate response or intolerance to conventional synthetic DMARDs: results from the RA-BUILD study. Ann Rheum Dis. 2017 Jan;76(1):88-95. doi: 10.1136/annrheumdis-2016-2100.
  50. England BR, Smith BJ, Baker NA, et al. 2022 American College of Rheumatology guideline for exercise, rehabilitation, diet, and additional integrative interventions for rheumatoid arthritis. Arthritis Care Res (Hoboken). 2023 Aug;75(8):1603-1615. doi: 10.1002/acr.25117. PMID: 37227116
  51. National Institute for Health and Care Excellence (NICE). Rheumatoid arthritis in adults: management. NICE. https://www.nice.org.uk/. 12 Oct 2020.
  52. Smolen JS, Aletaha D. Assessment of rheumatoid arthritis disease activity and physical function. UpToDate. https://www.uptodate.com. 22 Nov 2022.
  53. Smolen JS. Undifferentiated early inflammatory arthritis in adults. UpToDate. https://www.uptodate.com. 28 May 2022.
  54. Ito H, Nishida K, Kojima T, et al. Non-drug and surgical treatment algorithm and recommendations for the 2020 update of the Japan College of Rheumatology clinical practice guidelines for the management of rheumatoid arthritis – secondary publication. Mod Rheumatol. 2023 Jan;33(1):35-45. doi: 10.1093/mr/roac019. PMID: 35294030
  55. Studenic P, Aletaha D, de Wit M, et al. American College of Rheumatology/EULAR remission criteria for rheumatoid arthritis: 2022 revision. Arthritis Rheumatol. 2023 Jan;75(1):15-22. doi: 10.1002/art.42347. PMID: 36274193
  56. Baker J. Diagnosis and differential diagnosis of rheumatoid arthritis. UpToDate. https://www.uptodate.com/. 21 Mar 2024.
  57. Cohen S, Mikuls T. Initial treatment of rheumatoid arthritis in adults. UpToDate. https://www.uptodate.com/. 05 Jan 2024.
  58. Gao Y, Zhang Y, Liu X. Rheumatoid arthritis: Pathogenesis and therapeutic advances. MedComm (2020). 2024 Apr;5(3):e509. doi: 10.1002/mco2.509. PMID: 38469546